Hepatitis B Vaccination: Indications, Dosing, and Contraindications
Universal Vaccination Recommendation
All adults aged 19-59 years should receive hepatitis B vaccination, regardless of risk factors, and adults aged ≥60 years with risk factors should also be vaccinated. 1 This universal approach eliminates the need for risk factor screening and disclosure, which has historically limited vaccination coverage. 1
Indications for Vaccination
Universal Groups
- All adults aged 19-59 years (including pregnant persons) 1
- Adults aged ≥60 years with risk factors for hepatitis B 1
- Adults aged ≥60 years without known risk factors may receive vaccination (permissive recommendation) 1
High-Priority Risk Groups
- Persons with chronic liver disease (cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, elevated ALT/AST >2× upper limit of normal) 1
- Persons with HIV infection 1
- Healthcare personnel and public safety workers with exposure to blood 2
- Persons on hemodialysis 1, 2
- Men who have sex with men 1, 2
- Current or past persons who inject drugs 1, 2
- Persons who are incarcerated 1
- Household, sexual, or needle-sharing contacts of HBsAg-positive persons 2
- Persons born in countries with HBV prevalence ≥2% 2
- Persons needing immunosuppressive therapy 2
Dosing Schedules by Vaccine Type
Standard Adult Formulations (≥18 years)
Heplisav-B (preferred for most adults due to superior compliance):
- 20 μg (0.5 mL) at 0 and 1 month 1
- Two-dose series provides rapid completion 3
- Not established for hemodialysis patients or pregnant women 1
PreHevbrio (three-antigen vaccine):
Recombivax HB:
- Standard dose (≥20 years): 10 μg (1.0 mL) at 0,1, and 6 months 1
- Hemodialysis/immunocompromised (≥20 years): 40 μg (1.0 mL) at 0,1, and 6 months 1
Engerix-B:
- Standard dose (≥20 years): 20 μg (1.0 mL) at 0,1, and 6 months 1
- Hemodialysis/immunocompromised (≥20 years): 40 μg (2.0 mL) at 0,1,2, and 6 months (4-dose series) 1
Twinrix (HepA-HepB combination):
- Standard schedule: 20 μg HBsAg (1.0 mL) at 0,1, and 6 months 1
- Accelerated schedule: 0 days, 7 days, 21-30 days, and 12 months 1
Adolescent Formulations (11-19 years)
Recombivax HB:
- Ages 11-15: 10 μg (0.5 mL) at 0 and 4-6 months (2-dose series) OR standard 3-dose series 1, 4
- Ages 11-19: 5 μg (0.5 mL) at 0,1, and 6 months (3-dose series) 4
Engerix-B:
Special Populations
Pregnant women requiring vaccination:
- Use Engerix-B, Recombivax HB, or Twinrix only 1
- Avoid Heplisav-B and PreHevbrio (insufficient pregnancy safety data) 1
Hemodialysis patients:
- Use Recombivax HB 40 μg or Engerix-B 40 μg (4-dose series) 1
- Annual anti-HBs testing; administer booster when <10 mIU/mL 2
Management of Interrupted Series
If the vaccination series is interrupted, do NOT restart—simply continue with the next dose. 2, 4
Minimum Intervals
- Between doses 1 and 2: ≥4 weeks 2, 4
- Between doses 2 and 3: ≥8 weeks 2, 4
- Between doses 1 and 3: ≥16 weeks 2, 4
Key Points
- Doses given ≤4 days before the minimum interval are considered valid 2
- Exception: The 4-day grace period does NOT apply to the accelerated Twinrix schedule 2
- Different vaccine brands may be used interchangeably to complete a series 2, 4
Prevaccination Testing
Routine prevaccination serologic testing is NOT required for most adults. 1 However, testing for HBsAg, anti-HBs, and anti-HBc should be considered for:
- Household, sexual, or needle contacts of HBsAg-positive persons 2
- HIV-positive persons 2
- Persons with elevated ALT/AST of unknown etiology 2
- Hemodialysis patients 2
- Men who have sex with men 2
- Current or past persons who inject drugs 2
- Persons born in countries with HBV prevalence ≥2% 2
- Persons needing immunosuppressive therapy 2
Critical caveat: Lack of testing capacity must NEVER delay vaccination—administer the first dose immediately after blood collection for testing. 1, 2
Postvaccination Testing
Routine postvaccination serologic testing is NOT recommended for healthy adults. 2, 4
Groups Requiring Postvaccination Testing (1-2 months after series completion)
- Healthcare personnel and public safety workers 2
- Hemodialysis patients 2
- HIV-infected persons 2
- Other immunocompromised persons 2
- Infants born to HBsAg-positive mothers 2
Interpretation
- Anti-HBs ≥10 mIU/mL: Seroprotective response achieved 2
- Anti-HBs <10 mIU/mL: Administer 1 additional dose, retest 1-2 months later 2
- If still <10 mIU/mL after single additional dose: Complete a second full series (total 6 doses), retest 1-2 months after final dose 2
Revaccination and Booster Doses
Booster doses are NOT routinely recommended for immunocompetent persons who completed the primary series. 2
Exceptions Requiring Revaccination
- Hemodialysis patients: Annual anti-HBs testing; booster when <10 mIU/mL 2
- Other immunocompromised persons: Consider annual testing and boosters for ongoing exposure risk 2
- Healthcare personnel with anti-HBs <10 mIU/mL: Administer additional dose(s) as described above 2
Contraindications
The only absolute contraindication to hepatitis B vaccination is a history of severe allergic reaction (anaphylaxis) to a previous dose or vaccine component. 5
Precautions
- Moderate or severe acute illness (defer vaccination until recovery) 5
- Pregnancy is NOT a contraindication—use Engerix-B, Recombivax HB, or Twinrix 1
Common Pitfalls to Avoid
- Do NOT use Heplisav-B or PreHevbrio in pregnant women or hemodialysis patients (insufficient safety/efficacy data) 1
- Do NOT restart an interrupted series—continue with the next scheduled dose 2, 4
- Do NOT delay vaccination awaiting serologic test results in high-risk populations 1, 2
- Do NOT use the 2-dose Recombivax HB schedule for persons aged ≥16 years (licensed only for ages 11-15) 4
- Do NOT routinely test healthy adults postvaccination—reserve testing for high-risk occupational/medical groups 2, 4
- Do NOT assume different vaccine brands cannot be interchanged—they can be used to complete a series 2, 4